Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Conflicts of Interest The authors declare no conflicts of interest. References 1, , , et al., “Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma: Overview of the Descriptive Epidemiology,” British Journal of Hematology 139, no. 5 (2007): 809–819, https://doi.org/10.1111/j.1365-2141.2007.06856.x. 2, “Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review,” JAMA 329, no. 11 (2023): 918–932, https://doi.org/10.1001/jama.2023.1946.
Abstract Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B-cell lymphoma or acute lymphoblastic leukemia. Impaired T-cell fitness of CLL patients may be involved in treatment failure. Less-differentiated naïve-like T cells play an important role in CART expansion and long-term persistence in vivo. These cells are sparse in CLL patients.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
